Hospira To Fed. Circ.: Don't Alter On-Sale Rule For Patents
Generic drugmaker Hospira urged the full Federal Circuit bench Thursday not to exempt medicine-manufacturing contracts from the types of product sales that bar patent applications, arguing such a "sweeping change" in...To view the full article, register now.
Already a subscriber? Click here to view full article